Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Non-Current Assets (2017 - 2025)

Inmune Bio (INMB) has disclosed Non-Current Assets for 9 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 86.98% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, down 86.98% year-over-year, with the annual reading at $2.2 million for FY2025, 86.98% down from the prior year.
  • Non-Current Assets hit $2.2 million in Q4 2025 for Inmune Bio, down from $2.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $17.3 million in Q4 2021 to a low of $1.6 million in Q2 2025.
  • Historically, Non-Current Assets has averaged $14.8 million across 5 years, with a median of $17.0 million in 2024.
  • Biggest five-year swings in Non-Current Assets: grew 4.01% in 2021 and later tumbled 90.27% in 2025.
  • Year by year, Non-Current Assets stood at $17.3 million in 2021, then dropped by 1.26% to $17.1 million in 2022, then decreased by 0.36% to $17.1 million in 2023, then fell by 0.93% to $16.9 million in 2024, then tumbled by 86.98% to $2.2 million in 2025.
  • Business Quant data shows Non-Current Assets for INMB at $2.2 million in Q4 2025, $2.7 million in Q3 2025, and $1.6 million in Q2 2025.